La Food and Drug Administration (FDA) a élargi l'usage pédiatrique de l'implant cochléaire assisté par robot au profit de la technologie iotaSOFT® développée par iotaMotion, permettant désormais son utilisation dès l'âge de quatre ans. Cette avancée prometteuse vise à optimiser la précision des interventions chirurgicales pour préserver les structures intracochléaires et standardiser les approches opératoires. Soutenue par des résultats cliniques encourageants, elle pourrait significativement améliorer la prise en charge des pertes auditives chez les enfants, dans un contexte où le recours à l'implant cochléaire reste encore limité au niveau mondial.

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  Longview News-Journal

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  PR Newswire

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  PR Newswire

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  Morningstar

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  WV News

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  Yahoo Finance

iotaMotion Announces Issuance of U.S. Patent for Robotic-Assisted Cochlear Implantation Technology  PR Newswire UK

Reported Tuesday, Feb 3 - 7:07am EST (TheFly subscription required to read more.)

IotaMotion recently secured a new U.S. patent, enhancing its position as a leader in robotic-assisted cochlear implant surgery with iotaSOFT®, the first FDA-authorized system.

IotaMotion solidifies its leadership in robotic cochlear implant technology with the issuance of a new U.S. patent for its innovative iotaSOFT system.

IotaMotion bolsters its leadership in robotic-assisted cochlear implantation by securing a new U.S. patent for groundbreaking surgical technology.

IotaMotion, Inc. strengthens its position in robotic cochlear implant systems with a new patent, enhancing precision in surgeries and patient outcomes.

IotaMotion, a leader in robotic cochlear implant technology, has secured a new US patent, enhancing their innovative portfolio aimed at improving auditory health.

iotaMotion has achieved FDA approval for its iotaSOFT® robotic system, enhancing cochlear implant access for children aged four and older.

iotaMotion, a pioneer in cochlear implantation technology, has received FDA approval for pediatric use of the iotaSOFT® robotic system, enhancing access for young patients.

iotaMotion has received FDA clearance to expand the pediatric use of its iotaSOFT® system, providing advanced robotic-assisted cochlear implant technology for children.

iotaMotion has received FDA clearance to expand the pediatric application of its robotic-assisted cochlear implant insertion system, iotaSOFT®. This innovation enhances surgical precision for children ages four and above.

iotaMotion has gained FDA approval to use its iotaSOFT® robotic-assisted cochlear implant system in children aged four and older, broadening access.

iotaMotion's FDA clearance expands usage of the iotaSOFT® robotic system for cochlear implant surgeries in children 4 years and older.

iotaMotion has celebrated a significant milestone by completing over 1,000 cochlear implant procedures with its robotic-assisted iotaSOFT system, transforming surgical outcomes.

iotaMotion, Inc. has completed over 1,000 clinical procedures using its iotaSOFT® robotic-assisted system, revolutionizing cochlear implant surgery.

iotaMotion, Inc. has surpassed 1,000 clinical procedures with its iotaSOFT® system, marking a significant advancement in cochlear implant surgery and patient outcomes.

iotaMotion has achieved a significant milestone by surpassing 1,000 clinical procedures using their iotaSOFT system in cochlear implant surgeries.

iotaMotion, Inc. has announced a groundbreaking US patent for robotic-assisted cochlear implantation technology, enhancing surgical precision and patient outcomes.